Showing 1,601 - 1,620 results of 1,859 for search '"Immunotherapy"', query time: 0.07s Refine Results
  1. 1601

    Effects of NK cell-related lncRNA on the immune microenvironment and molecular subtyping for pancreatic ductal adenocarcinoma by Jinze Li, Chuqi Xia, Yuxuan Li, Hanhan Liu, Cheng Gong, Daoming Liang

    Published 2025-01-01
    “…BackgroundPatients with pancreatic ductal adenocarcinoma (PDAC) face a highly unfavorable outcome and have a poor response to standard treatments. Immunotherapy, especially therapy based on natural killer (NK) cells, presents a promising avenue for the treatment of PDAC.AimsThis research endeavor seeks to formulate a predictive tool specifically designed for PDAC based on NK cell-related long non-coding RNA (lncRNA), revealing new molecular subtypes of PDAC to promote personalized and precision treatment.MethodsUtilizing the Tumor Immune Single-cell Hub 2 platform, we discovered genes associated with NK cells in PDAC. …”
    Get full text
    Article
  2. 1602
  3. 1603

    Functionalized biomimetic nanoparticles loaded with salvianolic acid B for synergistic targeted triple-negative breast cancer treatment by Nuo Cheng, Qianqian Zhou, Zongfang Jia, Yang Mu, Sheng Zhang, Lei Wang, Yunna Chen

    Published 2025-02-01
    “…Finally, this study presents a precise and effective new strategy for TNBC immunotherapy on the basis of the differentiation of ''cold'' and ''hot'' microenvironments.…”
    Get full text
    Article
  4. 1604

    Interferon-gamma rescues dendritic cell calcineurin-dependent responses to Aspergillus fumigatus via Stat3 to Stat1 switching by Amit Adlakha, Thomas J. Williams, Xinxin Shou, Anna K. Reed, Boris Lenhard, Darius Armstrong-James

    Published 2025-02-01
    “…These findings provide key insight into the mechanisms of immunotherapy in organ transplant recipients with invasive fungal diseases.…”
    Get full text
    Article
  5. 1605

    The effect of conditioned media on the cellular proliferation of pancreatic cancer cells, pancreatic stellate cells, and myeloid-derived suppressor cells by Y. Chong, S. Samsudin, D. Bahrani, C. Chang, A. Masamune, S. Ng, N. Ismail, K. Ho

    Published 2025-01-01
    “…Factors from primary tumour cells support cancer cell survival more than those from metastatic cells, indicating potential targets for immunotherapy in early-stage cancers.…”
    Get full text
    Article
  6. 1606

    Identification of critical biomarkers and immune landscape patterns in glioma based on multi-database by Hanzhang Yuan, Jingsheng Cheng, Jun Xia, Zeng Yang, Lixin Xu

    Published 2025-01-01
    “…Conclusion SLC8A2, ATP2B3, and SRCIN1 were identified as underlying biomarkers for glioma associated with prognosis assessments and personal immunotherapy. Graphical Abstract…”
    Get full text
    Article
  7. 1607

    pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG by Jing Wu, Shuang Li, Tete Li, Xinping Lv, Mingyou Zhang, Guoxia Zang, Chong Qi, Yong-Jun Liu, Liang Xu, Jingtao Chen

    Published 2019-01-01
    “…These results are relevant to the further study of the role and mechanism of pDC-induced antitumor effects and may aid in the development of a new strategy for future tumor immunotherapy.…”
    Get full text
    Article
  8. 1608
  9. 1609

    Stemness-related gene signatures as a predictive tool for breast cancer radiosensitivity by Jinzhi Lai, Rongfu Huang, Jingshan Huang

    Published 2025-01-01
    “…Notably, patients in the RS group also exhibited a significantly better response to immunotherapy compared to the RR group. We established a radioresistant BRCA cell line using the MCF-7 breast cancer cell line. …”
    Get full text
    Article
  10. 1610

    Gastric cancer liver metastases in China: a real-world, multicentre, prospective, observational cohort study protocol by Yi Liu, Lin Chen, Hongqing Xi, Zhida Chen, Tingting Lu, Yunhe Gao, Gan Zhang, Haiya Zhang

    Published 2025-01-01
    “…The different therapeutic modalities employed in the treatment of GCLM, including surgery, chemotherapy and immunotherapy, will be recorded as secondary endpoints. …”
    Get full text
    Article
  11. 1611

    Identification of Survival Risk and Immune-Related Characteristics of Kidney Renal Clear Cell Carcinoma by Xiaobin Wu, Yonghui Liang, Xian Chen, Xiangyang Long, Wujun Xu, Li Liu, Binhui Wang, Xiong Zou

    Published 2022-01-01
    “…These comprehensive immune assessments and survival predictions, integrating multiple aspects of data and clinical information, can provide additional value to the current Tumor Node Metastasis staging system for risk stratification of KIRC and may facilitate the development of KIRC immunotherapy.…”
    Get full text
    Article
  12. 1612

    The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression by Yayun Zheng, Xue Ma, Dongmei Su, Yue Zhang, Lin Yu, Fangfei Jiang, Xue Zhou, Ying Feng, Fang Ma

    Published 2020-01-01
    “…In this review, we aim to discuss the similarities and differences between Siglec7 and Siglec9 and analyze their functions in virus infection and tumour progression in order to develop better anti-viral and anti-tumor immunotherapy in the future.…”
    Get full text
    Article
  13. 1613

    Colorimetric aptasensor coupled with a deep-learning-powered smartphone app for programmed death ligand-1 expressing extracellular vesicles by Adeel Khan, Adeel Khan, Haroon Khan, Nongyue He, Zhiyang Li, Heba Khalil Alyahya, Yousef A. Bin Jardan

    Published 2025-01-01
    “…Extracellular vesicles expressing programmed death ligand-1 (PD-L1) markers (PD-L1@EVs) in the blood are reported to be indicative of lung cancer and response to immunotherapy. Our approach is the development of a colorimetric aptasensor by combining the rapid capturing efficiency of (Fe3O4)-SiO2-TiO2 for EV isolation with PD-L1 aptamer-triggered enzyme-linked hybridization chain reaction (HCR) for signal amplification. …”
    Get full text
    Article
  14. 1614

    Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context by Valentine Wang, Barbara Savoldo, José-Arthur Guimaraes, Gianpietro Dotti, Loïc Reppel, Loïc Reppel, Danièle Bensoussan, Danièle Bensoussan

    Published 2025-01-01
    “…CAR-T cell therapy has revolutionized immunotherapy but its allogeneic application, using various strategies, faces significant challenges including graft-versus-host disease and graft rejection. …”
    Get full text
    Article
  15. 1615

    Targeted nanoliposomes for precision rheumatoid arthritis therapy: a review on mechanisms and in vivo potential by Rushikesh Girase, Nayan A. Gujarathi, Amey Sukhia, Sri Sai Nikitha Kota, Tulshidas S. Patil, Abhijeet A. Aher, Yogeeta O. Agrawal, Shreesh Ojha, Charu Sharma, Sameer N. Goyal

    Published 2025-12-01
    “…In the future, integrating these advanced liposomes with artificial intelligence, immunotherapy, and precision medicine holds great promise.…”
    Get full text
    Article
  16. 1616

    Exosomal PVRL4 Promotes Lung Adenocarcinoma Progression by Enhancing the Generation of Myeloid‐Derived Suppressor Cell‐Secreted TGF‐β1 by Yahai Liang, Jinmei Li, Lihua Zhang, Jinling Zhou, Meilian Liu, Xiaoxia Peng, Weizhen Zheng, Zhennan Lai

    Published 2025-01-01
    “…Conclusion Exosomal PVRL4 promoted LUAD progression by inducing the secretion of TGF‐β1 in MDSCs, indicating a novel direction for LUAD immunotherapy.…”
    Get full text
    Article
  17. 1617

    Topical transdermal administration of lenalidomide nanosuspensions-based hydrogels against melanoma: In vitro and in vivo studies by Mengdi Zhang, Haiying Qiu, Zheyi Han, Yazhong Ma, Jingjing Hou, Jingwei Yuan, Haiyan Jia, Menglu Zhou, Hongjie Lu, Yan Wu

    Published 2025-06-01
    “…Percutaneous neoadjuvant therapy has proven effective in diminishing tumor size and the surgical intervention area, which couldeffectively mitigate the risk of tumor recurrence and enhance immunotherapy efficacy. Lenalidomide, an approved medication orally used to treat myeloma, was loaded into nanosuspensions-based hydrogels (Len-NBHs) for transdermal administration as a percutaneous neoadjuvant therapy. …”
    Get full text
    Article
  18. 1618

    Increased SOAT2 expression in aged regulatory T cells is associated with altered cholesterol metabolism and reduced anti-tumor immunity by Mingjiong Zhang, Jiahua Cui, Haoyan Chen, Yifan Cheng, Qiaoyu Chen, Feng Zong, Xiao Lu, Lang Qin, Yu Han, Xingwang Kuai, Yuxing Zhang, Minjie Chu, Shuangshuang Wu, Jianqing Wu

    Published 2025-01-01
    “…Our study thus identifies a potential mechanism responsible for altered Treg function in the context of immune aging, and also implicates SOAT2 as a potential target for tumor immunotherapy.…”
    Get full text
    Article
  19. 1619

    Mining Potential Drug Targets and Constructing Diagnostic Models for Heart Failure Based on miRNA-mRNA Networks by Xiangming Fang, Rensheng Song, Jiaxing Wei, Qin Liao, Zhenhong Zeng

    Published 2022-01-01
    “…This provides a new promising direction to improve the diagnosis, prognosis, and treatment outcome and guide more effective immunotherapy strategies of HF.…”
    Get full text
    Article
  20. 1620

    Preferential Expression of B7-H6 in Glioma Stem-Like Cells Enhances Tumor Cell Proliferation via the c-Myc/RNMT Axis by Hanqing Chen, Yundi Guo, Jing Sun, Jun Dong, Qinghua Bao, Xueguang Zhang, Fengqing Fu

    Published 2020-01-01
    “…Thus, our findings suggest B7-H6 as a potential molecule for glioma stem cell targeted immunotherapy.…”
    Get full text
    Article